Glioblastoma (IDH-WT, WHO grade 4) · line 1 · Hypofractionated radiotherapy for GBM
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-HYPOFRACTIONATED-RT-GBM |
| ID | IND-GBM-NEWLY-DIAGNOSED-ELDERLY-HYPORT |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | DIS-GBM |
| Sources | SRC-CCTG-CE6-PERRY-2017 SRC-EANO-GBM-2024 SRC-NCCN-CNS-2025 SRC-NORDIC-GBM-MALMSTROM-2012 |
Notes
Hypofractionated RT for GBM: two validated schedules: (1) 40 Gy / 15 fractions (2.67 Gy/fx, 3 weeks) — CCTG CE.6 schedule (2) 34 Gy / 10 fractions (3.4 Gy/fx, 2 weeks) — Nordic schedule Both are NCCN acceptable. 40 Gy/15 more commonly used when concurrent TMZ is added (better tolerability with 3-week course than 2-week). RT is not modelable per PROPOSAL §17 — this indication captures the TMZ chemo backbone; RT schedule is free-text MDT decision.
Used By
Algorithms
ALGO-GBM-NEWLY-DIAGNOSED-1L- ALGO-GBM-NEWLY-DIAGNOSED-1L
Indication
IND-GBM-NEWLY-DIAGNOSED-ELDERLY-TMZ- IND-GBM-NEWLY-DIAGNOSED-ELDERLY-TMZ